Treatment-emergent adverse events occurred in six (75%) participants; two were of "moderate" severity (moderate flare of plaque psoriasis and moderate sore throat). Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial. I Br J Dermatol i 2023; 189:161-169. https://doi.org/10.1093/bjd/ljad128 Generalized pustular psoriasis (GPP) is a rare, debilitating autoinflammatory disorder that presents with flares of widespread sterile pustules and erythema, and is accompanied by systemic inflammation. [Extracted from the article]